Five Below (FIVE) Valuation in Focus After Upbeat Earnings, Guidance Raise and Non-Holiday Sales Milestone

When a company beats earnings expectations and then raises its own guidance, investors always sit up and take notice. That is exactly what just happened with Five Below (FIVE), as it posted second-quarter results that came in above estimates and nudged its outlook for both the third quarter and full year even higher. Perhaps most intriguing, Five Below crossed a milestone by surpassing $1 billion in sales outside of its typical holiday-driven quarter. This signals that shoppers' demand for its discount goods is no longer just a seasonal trend.

This upbeat news arrives with shares having returned nearly 80% over the past year and a remarkable 53% year-to-date. While momentum is clearly building, the company has also been executing on store expansions in key markets like Baltimore and Richland, as well as delivering ongoing annual revenue and net income growth above 8%. With the consistent raise in guidance, there is real evidence of operational strength as Five Below heads into the all-important holiday shopping season.

With the stock on a hot streak and management signaling further growth, the big question is whether Five Below is undervalued right now or if the market has already priced in next year’s gains.

Advertisement

Most Popular Narrative: 3.7% Undervalued

The most widely followed narrative suggests Five Below is currently undervalued by 3.7%, implying modest upside relative to its calculated fair value.

Five Below's commitment to providing extreme value and trend-right products at low price points is driving broad-based transaction growth. This growth is especially notable as consumers across demographics become increasingly value-focused due to persistent economic pressures. These factors are expanding store traffic and the addressable market, supporting higher revenue and the potential for sustained comparable sales growth.

Want to know what sends Five Below’s valuation above peers and keeps analysts bullish? This story is powered by aggressive growth forecasts and surprisingly ambitious assumptions about its future market reach and profitability. Curious how these strong expectations shape the share price? Read on to see which financial leaps drive this fair value call.

Result: Fair Value of $157.11 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, ongoing tariff pressures and rising labor costs could quickly erode margins. This could make it harder for Five Below to meet growth expectations.

Find out about the key risks to this Five Below narrative.

Another View: Is the Market Overlooking Something?

Looking at Five Below’s valuation through the lens of its price-to-earnings ratio compared to the industry puts things in a different light. This approach actually suggests the stock is overvalued. Could expectations be running ahead of reality?

See what the numbers say about this price — find out in our valuation breakdown.

NasdaqGS:FIVE PE Ratio as at Sep 2025
NasdaqGS:FIVE PE Ratio as at Sep 2025

Stay updated when valuation signals shift by adding Five Below to your watchlist or portfolio. Alternatively, explore our screener to discover other companies that fit your criteria.

Build Your Own Five Below Narrative

If you want to dig deeper or see the story from your own perspective, you can quickly build your own unique narrative and analysis. Do it your way.

A great starting point for your Five Below research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.

Looking for More Investment Opportunities?

Take action before your next move slips by. Outsmart the crowd by targeting new trends and under-the-radar opportunities using our handpicked investment screens below.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Kshitija Bhandaru

Kshitija Bhandaru

Kshitija (or Keisha) Bhandaru is an Equity Analyst at Simply Wall St and has over 6 years of experience in the finance industry and describes herself as a lifelong learner driven by her intellectual curiosity. She previously worked with Market Realist for 5 years as an Equity Analyst.

About NasdaqGS:FIVE

Five Below

Operates as a specialty value retailer in the United States.

Flawless balance sheet with solid track record.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1157.5% undervalued
38 users have followed this narrative
2 users have commented on this narrative
6 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7721.4% undervalued
59 users have followed this narrative
0 users have commented on this narrative
7 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9218.9% undervalued
21 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$19013.7% undervalued
19 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative

Updated Narratives

AE
ASML logo
Aequitas on ASML Holding ·

ASML Will Reign as the Kingpin of the Semiconductor Supply Chain

Fair Value:€1.87k16.5% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AE
FTNT logo
Aequitas on Fortinet ·

Fortinet, compounding Cyber Security Player.

Fair Value:US$116.8430.4% overvalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AE
CSU logo
Aequitas on Constellation Software ·

Constellation Software: A Proven Serial Acquirer at a Discount

Fair Value:CA$3.72k28.3% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.6% undervalued
70 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative
CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.919.1% undervalued
72 users have followed this narrative
0 users have commented on this narrative
5 users have liked this narrative
TR
tripledub
GOOGL logo
tripledub on Alphabet ·

Warren Buffett Just Bet $10 Billion on Google. The Catch? You May Already Be Too Late.

Fair Value:US$23039.0% overvalued
94 users have followed this narrative
1 users have commented on this narrative
18 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

0
|
0